Tag: intracellular tyrosine kinase inhibitor

1. The SENSCIS trial, a randomized control trial studying the efficacy of nintedanib, an intracellular tyrosine kinase inhibitor, versus placebo on respiratory function among patients with interstitial lung disease mediated by systemic sclerosis, found a slower forced vital capacity (FVC) decline in patients treated with nintedanib. 2. There were no...